June 12th 2021
By Meaghan Rose Smith
In this column, officials from the Biosimilars Forum and Xcenda discuss how biosimilar competition has lowered prices of originator biologics and improved patient access.
June 11th 2021
In part 2 of this panel discussion, 3 experts on India’s biologics industry discuss whether biosimilars can be produced affordably in the country and ways of improving the industry’s image.
June 10th 2021
By Tony Hagen
The European Union makes it far more difficult to obtain patents on biologics, reducing the likelihood of patent “thickets” that stifle competition, the Matrix Global Advisors report states.
June 9th 2021
In part 1 of this panel discussion, 3 experts on India’s biologics industry explain what’s missing from current biosimilar regulation and what the country needs to do for its products to compete internationally.
June 8th 2021
Bio-Thera has set up a psoriatic arthritis clinical trial for BAT2506, which references Simponi.
June 5th 2021
By Sarfaraz K. Niazi, PhD
Sarfaraz K. Niazi, PhD, a member of The Center for Biosimilars® Advisory Board, reports on his citizen petition to the FDA to rationalize testing of biosimilars.
June 1st 2021
Biosimilar manufacturers may encounter roadblocks in the months and years ahead, and generics manufacturers will find they've hit a ceiling, according to Adam Fein, PhD, CEO of the Drug Channels Institute.
May 28th 2021
More transparency in how health care money is spent could improve utilization and efficiency, panelists said at the Medicines for Europe event.
May 22nd 2021
Prestige BioPharma aims to expand its drug pipeline with a $152 million research and development facility.
May 21st 2021
Biosimilar education can increase physician motivation to prescribe these alternatives to costly originator products, panelists said in a Sandoz/Reuters discussion.
